DANVILLE, Pa., RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 25,
2017 /PRNewswire/ -- In an effort to improve health
outcomes of people with type 2 diabetes, Geisinger and Boehringer
Ingelheim, on behalf of its diabetes alliance with Eli Lilly and
Company (NYSE: LLY), today announced a major collaboration to
develop a risk-prediction model for three critical health outcomes
commonly associated with type 2 diabetes that have long-term impact
and cost-of-care implications: cardiovascular death, kidney failure
and hospitalization for heart failure.
The new model will allow healthcare professionals to predict
which adults with type 2 diabetes are most at risk for developing
these serious – and costly – health consequences. The model will be
created using Geisinger de-identified electronic health record data
(i.e., demographics, vital signs, medical history, current
medications and laboratory tests). Ultimately, a successful model
should allow for the development of more precise treatment pathways
for people with type 2 diabetes; pathways that align with quality
guidelines aiming to improve patient outcomes, quality and total
cost of care.
Approximately 30 million Americans have diabetes, and nearly 24
percent of Americans with diabetes are undiagnosed. People with
diabetes are two to four times more likely to develop
cardiovascular disease than people without
diabetes. Approximately 68 percent of deaths in people with
type 2 diabetes in the U.S. are caused by cardiovascular
disease.
"Our partnership with Boehringer Ingelheim will use real-world
data and predictive modeling to deploy precision healthcare
strategies to bring the most value to the people we care for," said
Brent Williams, Geisinger assistant
professor of epidemiology. "We hope the knowledge gained from this
predictive model can help healthcare providers better target their
treatment recommendations for people with type 2 diabetes and, as a
result, lower their risk for these serious diabetes-related
consequences."
Despite recent advances in treatment, cardiovascular disease
remains the leading cause of death associated with diabetes, and
diabetes is the number one cause of kidney failure in the U.S. The
financial burden of healthcare for cardiovascular conditions in
people with diabetes is also immense, costing the U.S. upwards of
$23 billion per year. Efforts such as
this partnership may offer long-term savings and solutions that
improve outcomes and lower total cost of care.
"Since people with diabetes are two to four times more likely to
develop cardiovascular disease than people without diabetes, novel
approaches to mitigate cardiovascular risk and improve patient care
continue to be a priority," said Christine
Marsh, vice president, Market Access, Boehringer Ingelheim
Pharmaceuticals, Inc. "We believe this initiative to develop a
predictive risk model is very timely, as recent research has
provided more practical knowledge about how to reduce
cardiovascular risk in people with type 2 diabetes. Boehringer
Ingelheim and Lilly are proud to be a part of this collaboration,
which will address a pressing need of people with type 2 diabetes
and the healthcare community that cares for them."
About Geisinger
Geisinger is an integrated health
services organization widely recognized for its innovative use of
the electronic health record and the development of innovative care
delivery models such as ProvenHealth Navigator®,
ProvenCare® and ProvenExperience®. As one of
the nation's largest health service organizations, Geisinger serves
more than 3 million residents throughout 45 counties in
central, south-central and northeast Pennsylvania, and also in southern
New Jersey at AtlantiCare, a
Malcolm Baldrige National Quality Award recipient. In 2017, the
Geisinger Commonwealth School of Medicine became the newest member
of the Geisinger Family. The physician-led system is comprised of
approximately 30,000 employees, including nearly 1,600
employed physicians, 13 hospital campuses, two research centers,
and a 551,000-member health plan, all of which leverage an
estimated $10.5 billion positive
impact on the Pennsylvania and
New Jersey economies. Geisinger
has repeatedly garnered national accolades for integration,
quality and service. In addition to fulfilling its patient care
mission, Geisinger has a long-standing commitment to medical
education, research and community service. For more information,
visit www.geisinger.org, or connect with us on Facebook,
Instagram, LinkedIn and Twitter.
Boehringer Ingelheim and Eli Lilly and Company
In
January 2011, Boehringer Ingelheim
and Eli Lilly and Company announced an alliance in diabetes that
centers on compounds representing several of the largest diabetes
treatment classes. This alliance leverages the strengths of two of
the world's leading pharmaceutical companies. By joining forces,
the companies demonstrate commitment in the care of patients with
diabetes and stand together to focus on patient needs. Find out
more about the alliance at www.boehringer-ingelheim.com or
www.lilly.com.
Given the critical connection between diabetes and
cardiovascular disease, Boehringer Ingelheim and Lilly are
committed to providing a wide range of diabetes therapies along
with programs and support to raise awareness, understanding and
action toward reducing the impact of cardiovascular disease in
people with type 2 diabetes.
About Boehringer Ingelheim
Boehringer Ingelheim
Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary
of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world's top 20 pharmaceutical
companies. Headquartered in Ingelheim, Germany, the company operates globally with
approximately 50,000 employees. Since its founding in 1885, the
company has remained family-owned and today creates value through
innovation for three business areas including human
pharmaceuticals, animal health and biopharmaceutical contract
manufacturing.
Boehringer Ingelheim is committed to improving lives and
providing valuable services and support to patients and their
families. Our employees create and engage in programs that
strengthen our communities. Please visit our website to learn more
about how we make more health for more people through our Corporate
Social Responsibility initiatives.
In 2016, Boehringer Ingelheim achieved net sales of about
$17.6 billion (15.9 billion euros). R&D expenditure
corresponds to 19.6 percent of its net sales.
For more information please visit www.boehringer-ingelheim.us,
or follow us on Twitter @BoehringerUS.
About Lilly Diabetes
Lilly has been a global leader
in diabetes care since 1923, when we introduced the world's first
commercial insulin. Today we are building upon this heritage by
working to meet the diverse needs of people with diabetes and those
who care for them. Through research and collaboration, a wide range
of therapies and a continued determination to provide real
solutions—from medicines to support programs and more—we strive to
make life better for all those affected by diabetes around the
world. For more information, visit www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
www.lilly.com/newsroom/social-channels.
CR-LLY
MPR-US-100048
CONTACTS:
Jennifer Forsyth
Director, Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: jennifer.forsyth@boehringer-ingelheim.com
Phone: 203-791-5889
Molly
McCully
Communications Manager
Lilly Diabetes
Email: mccully_molly@lilly.com
Phone: 317-478-5423
David Stellfox
Geisinger
Email: dbstellfox@geisinger.edu
Phone: 570-214-6549
View original content with
multimedia:http://www.prnewswire.com/news-releases/geisinger-and-boehringer-ingelheim-collaborate-to-create-a-predictive-model-to-help-improve-health-outcomes-for-people-with-type-2-diabetes-at-greatest-risk-of-serious-long-term-complications-including-cardiovascular-death-300524467.html
SOURCE Eli Lilly and Company